The following is a review of diagnostic product developments worldwideThe information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.
The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.
Product developments in March 2005
Abbott and BioCurex entered into a licensing agreement for BioCurex's RECAF technology. The receptor for alpha-fetoprotein, RECAF is found on malignant cells from a variety of cancer cell types but is absent in most normal and benign cells. Abbott obtains worldwide, semi-exclusive rights to commercialize products using BioCurex's RECAF technology.
Beckman Coulter, Inc. introduced its new Cell Lab IC 100 image cytometer, a fully automated system for high-throughput imaging and analysis of cell populations for quantitative cellular analysis. The system is built upon the technology Beckman Coulter acquired from Q3DM, Inc. and expands the company's offering of cellular analysis tools.
bioMérieux, Inc. received FDA clearance to market its VITEK 2 Compact, an automated bacterial identification and antibiotic susceptibility testing system designed for small to mid-sized microbiology laboratories.
Cygnus, Inc. completed the sale of substantially all of its assets (other than cash and cash equivalents, accounts receivable, and its rights in the arbitration matter with Ortho-McNeil Pharmaceutical, Inc.) to Animas Corporation and Animas Technologies LLC for $10 million in cash.
Gen-Probe received clearance to market its stand alone APTIMA assay for Neisseria gonorrhoeae (GC).
Instrumentation Laboratory (IL) received FDA clearance for its HemosIL D-Dimer assay that allows laboratories to use the test as an aid in the diagnosis of deep vein thrombosis (DVT) and pulmonary embolism (PE). HemosIL D-Dimer, a fully automated immunoturbidimetric assay to be run on the ACL family of coagulation analyzers.
Immunicon Corporation received FDA clearance for the CellTracks Analyzer II, a semi-automated fluorescence microscope used to enumerate fluorescently labeled cells that are immuno-magnetically selected and aligned. The system is for in vitro diagnostic use when used in tandem with specimen preparation equipment and reagents developed for the system.
Laboratory Corporation of America (LabCorp) acquired Esoterix, Inc. and Subsidiaries, a provider of specialty reference testing for approximately $150 million in cash. The transaction, which is subject to regulatory approval, is expected to close in the second quarter of 2005. Esoterix's menu includes hematopathology consultations, flow cytometry, cytogenetics, immunohistochemistry, coagulation, FISH, molecular genetics and tumor markers. Esoterix has nine laboratories in the United States and one in Western Europe, and includes the brands of Endocrine Sciences, Allergy Testing Labs, Cytometry Associates, and Colorado Coagulation Consultants.
Pall Corporation signed a new multi-year contract for leukocyte (white blood cell) reduction filters with Gambro BCT, Inc. Pall will be the sole source, global provider of leukoreduction filters for red cells, plasma and platelets for Gambro BCT's automated blood collection and whole blood processing systems.
Roche Diagnostics received FDA clearance to market its COBAS AmpliScreen HIV-1 and Hepatitis C (HCV) Tests to screen cadaveric organ and tissue donations. The expanded claim for screening blood samples from these donors is in addition to testing whole blood, source plasma and potential living organ donors.
Product developments - February 2005
Product Developments Worldwide | Research News | Health Care in Canada
Information Technology and Healthcare | Molecular Biology | Links
Send mail to email@example.com with questions or comments about this web site.
Concept and Design Blue Page
Last modified: April 4, 2005